

Aus der Klinik für Innere Medizin III  
Hämatologie, Onkologie und Transfusionsmedizin  
Der Medizinischen Fakultät der Charité – Universitätsmedizin Berlin

## **DISSERTATION**

Functional assessment of the multidrug resistance phenomenon  
following gamma-irradiation therapy

zur Erlangung des akademischen Grades  
Doctor medicinae (Dr.med.)

vorgelegt der Medizinischen Fakultät der Charité –  
Universitätsmedizin Berlin

von

Daniel Koychev  
aus: Plovdiv, Bulgarien

Gutachter: 1. Prof.Dr.med. U. Keilholz

2. Prof.Dr.med.Dr.rer.nat. I. Cascorbi

3. Priv.-Doz. Dr.Th.Gerloff

Datum der Promotion: 22.09.06

CONTENTS	Page
<b>1. INTRODUCTION</b>	<b>6</b>
<b>1.1. Cell resistance to chemotherapeutic drugs</b>	<b>6</b>
<b>1.2. Bendamustine, cisplatin and doxorubicin as an option in the treatment of cancer</b>	<b>8</b>
<b>1.3. The role of radiotherapy in the appearance of chemoresistance</b>	<b>9</b>
<b>1.4. Multidrug resistance proteins and the multidrug resistance phenotype</b>	<b>11</b>
<b>1.4.1. P-glycoprotein</b>	<b>11</b>
<b>1.4.2. Multidrug resistance-associated protein 1 (MRP1)</b>	<b>14</b>
<b>1.4.3. Lung resistance protein (LRP)</b>	<b>17</b>
<b>1.5. Modulation of the multidrug resistant phenotype by calcium antagonists</b>	<b>19</b>
<b>1.6. Therapy modalities in the treatment of breast and colon cancer</b>	<b>20</b>
<b>1.7. Thesis</b>	<b>22</b>
<b>2. MATERIALS AND METHODS</b>	<b>23</b>
<b>2.1. Materials</b>	<b>23</b>
<b>2.1.1. Common solutions and chemicals</b>	<b>23</b>
<b>2.1.2. RNA isolation solutions and buffers</b>	<b>23</b>
<b>2.1.3. Complementary DNA synthesis solutions and buffers</b>	<b>24</b>
<b>2.1.4. Polymerase chain reaction solutions and buffers</b>	<b>24</b>
<b>2.1.5. Solution, antibodies and reagents used in multidrug resistant protein staining and caspase-propidium iodide assay</b>	<b>25</b>
<b>2.1.6. Other chemicals</b>	<b>26</b>
<b>2.2. Cell culture and cell mediums</b>	<b>26</b>
<b>2.2.1. Cell mediums</b>	<b>26</b>
<b>2.2.2. Tumor cell lines</b>	<b>27</b>
<b>2.2.3. Laboratory inventory</b>	<b>28</b>
<b>2.2.4. Laboratory materials</b>	<b>29</b>
<b>2.3. Methods</b>	<b>30</b>

<b>2.3.1.</b>	<b>Cultivation of tumor cells</b>	<b>30</b>
<b>2.3.2.</b>	<b>Cell irradiation</b>	<b>30</b>
<b>2.3.3.</b>	<b>Cell harvest and Ficoll viable cell separation</b>	<b>31</b>
<b>2.3.4.</b>	<b>RNA isolation according the Qiagen protocol</b>	<b>32</b>
<b>2.3.5.</b>	<b>Quantitative and qualitative determination of total RNA</b>	<b>32</b>
<b>2.3.5.1.</b>	<b>Spectrophotometry</b>	<b>32</b>
<b>2.3.5.2.</b>	<b>Gel electrophoresis</b>	<b>33</b>
<b>2.3.6.</b>	<b>Complementary DNA synthesis</b>	<b>33</b>
<b>2.3.7.</b>	<b>Real-time quantitative polymerase chain reaction</b>	<b>34</b>
<b>2.3.8.</b>	<b>Fluorescent flow cytometry (FACS)</b>	<b>37</b>
<b>2.3.9.</b>	<b>FACS analysis and quantification of P-glycoprotein, MRP 1 and LRP</b>	<b>38</b>
<b>2.3.9.1.</b>	<b>Protocol for MRP1 and P-glycoprotein staining</b>	<b>38</b>
<b>2.3.9.2.</b>	<b>Protocol for LRP staining</b>	<b>39</b>
<b>2.3.10.</b>	<b>Incubation with cytotoxic drugs</b>	<b>40</b>
<b>2.3.11.</b>	<b>Evaluation of the calcium channel blocker verapamil as a P-glycoprotein and MRP1 activity modulator</b>	<b>41</b>
<b>2.3.12.</b>	<b>Detection of cell apoptosis and cell death</b>	<b>41</b>
<b>2.3.13.</b>	<b>Positive control for lrp, mrp1 and mdr1 mRNA as well as LRP, MRP1 and P-glycoprotein</b>	<b>43</b>
<b>2.4.</b>	<b>Statistical analysis</b>	<b>44</b>
<b>3.</b>	<b>RESULTS</b>	<b>45</b>
<b>3.1.</b>	<b>Expression of multidrug resistance-associated genes after irradiation</b>	<b>45</b>
<b>3.2.</b>	<b>Expression of multidrug resistance-associated proteins after irradiation</b>	<b>47</b>
<b>3.3.</b>	<b>Correlation between the expressions of multidrug resistance-associated genes and their protein products</b>	<b>49</b>
<b>3.4.</b>	<b>Co-expression of multidrug resistance-associated genes and proteins</b>	<b>51</b>
<b>3.5.</b>	<b>Cell sensitivity to cytotoxic drugs, following radiation treatment</b>	<b>52</b>
<b>3.6.</b>	<b>Correlation between multidrug resistance-associated proteins expression and cell viability following incubation with cytotoxic drugs</b>	<b>56</b>
<b>3.7.</b>	<b>Modulation of P-glycoprotein and MRP1 activity using verapamil</b>	<b>57</b>
<b>3.8.</b>	<b>Expression of multidrug resistance-associated genes and their proteins as a</b>	<b>59</b>

<b>late response to radiation</b>		
<b>3.9.</b>	<b>Cell drug resistance as a late response to irradiation</b>	<b>62</b>
<b>3.10.</b>	<b>Correlation between the drug sensitivity and LRP, MRP1 and P-glycoprotein expression</b>	<b>65</b>
<b>3.11.</b>	<b>Modulation of P-glycoprotein and MRP1 activity using verapamil</b>	<b>66</b>
<b>4.</b>	<b>DISCUSSION</b>	<b>68</b>
<b>4.1.</b>	<b>Relationship between mdr1/P-glycoprotein expression and radiation therapy</b>	<b>68</b>
<b>4.2.</b>	<b>Relationship between mrp1/MRP1 expression and radiation therapy</b>	<b>70</b>
<b>4.3.</b>	<b>Relationship between lrp/LRP expression and radiation therapy</b>	<b>71</b>
<b>4.4.</b>	<b>Multidrug resistance following radiation therapy</b>	<b>71</b>
<b>4.5.</b>	<b>Modulation of the multidrug resistance phenotype following irradiation - using calcium channels blocker – verapamil</b>	<b>73</b>
<b>4.6.</b>	<b>Conclusion</b>	<b>74</b>
<b>5.</b>	<b>SUMMARY</b>	<b>76</b>
<b>6.</b>	<b>ABBREVIATIONS</b>	<b>78</b>
<b>7.</b>	<b>REFERENCES</b>	<b>81</b>
<b>8.</b>	<b>CURRICULUM VITAE</b>	<b>93</b>
<b>9.</b>	<b>ACKNOWLEDGEMENTS</b>	<b>96</b>
<b>10.</b>	<b>ZUSAMMENFASSUNG</b>	<b>97</b>
<b>11.</b>	<b>ERKLÄRUNG</b>	<b>99</b>

## 11. ERKLÄRUNG

Ich **Daniel Koychev**, erkläre hiermit, dass ich die vorgelegte Dissertationsschrift mit dem Thema: FUNCTIONAL ASSESSMENT OF THE MULTIDRUG RESISTANCE PHENOMENON FOLLOWING GAMMA-IRRADIATION THERAPY, selbst verfasst und keine anderen als die angegebenen Quellen und Hilfsmittel benutzt, ohne die Hilfe Dritter verfasst und auch in Teilen keine Kopien anderer Arbeiten dargestellt habe.

02.01.2006

Unterschrift: